In hepatic impairment with high first-pass clearance, what is the recommended dosing strategy when intrinsic hepatic clearance is reduced?

• A. Increase the dose to overcome impairment
• B. Reduce the dose and monitor exposure; consider alternative routes with lower first-pass or adjust loading
• C. Stop therapy
• D. Dose as if there is no impairment

Answer: (B)

When a drug has high first-pass clearance, most of the drug is cleared by the liver on its first pass through after oral dosing. If hepatic impairment reduces intrinsic hepatic clearance, the liver’s ability to metabolize the drug decreases, which means the same oral dose can produce much higher systemic exposure (larger AUC) than before. To avoid toxicity or overly high levels, the dosing should be reduced and exposure carefully monitored. If possible, use a route or formulation that bypasses or lowers first-pass metabolism (for example, IV or another route with less hepatic first-pass effect) or adjust the loading dose to reach the desired therapeutic concentration without overshoot. Stopping therapy or treating as if there were no impairment would not address the increased exposure risk created by reduced hepatic metabolism.